nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—SLC29A1—Fluorouracil—skin cancer	0.585	1	CbGbCtD
Fludarabine—SLC28A3—nipple—skin cancer	0.00771	0.118	CbGeAlD
Fludarabine—RRM1—hair follicle—skin cancer	0.00634	0.0969	CbGeAlD
Fludarabine—SLC28A3—mammalian vulva—skin cancer	0.0045	0.0688	CbGeAlD
Fludarabine—RRM1—nipple—skin cancer	0.0043	0.0657	CbGeAlD
Fludarabine—SLC29A1—nipple—skin cancer	0.00349	0.0534	CbGeAlD
Fludarabine—DCK—nipple—skin cancer	0.00334	0.051	CbGeAlD
Fludarabine—POLA1—mammalian vulva—skin cancer	0.00316	0.0484	CbGeAlD
Fludarabine—RRM1—skin of body—skin cancer	0.00275	0.0421	CbGeAlD
Fludarabine—RRM1—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00256	0.157	CbGpPWpGaD
Fludarabine—RRM1—mammalian vulva—skin cancer	0.00251	0.0384	CbGeAlD
Fludarabine—SLC29A1—connective tissue—skin cancer	0.00248	0.0379	CbGeAlD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00234	0.143	CbGpPWpGaD
Fludarabine—RRM1—lymphoid tissue—skin cancer	0.00223	0.0341	CbGeAlD
Fludarabine—RRM1—female reproductive system—skin cancer	0.00215	0.0329	CbGeAlD
Fludarabine—SLC29A1—mammalian vulva—skin cancer	0.00204	0.0312	CbGeAlD
Fludarabine—DCK—mammalian vulva—skin cancer	0.00195	0.0298	CbGeAlD
Fludarabine—SLC29A1—lymphoid tissue—skin cancer	0.00181	0.0277	CbGeAlD
Fludarabine—RRM1—head—skin cancer	0.0018	0.0275	CbGeAlD
Fludarabine—SLC29A1—female reproductive system—skin cancer	0.00175	0.0267	CbGeAlD
Fludarabine—DCK—lymphoid tissue—skin cancer	0.00173	0.0265	CbGeAlD
Fludarabine—DCK—female reproductive system—skin cancer	0.00167	0.0255	CbGeAlD
Fludarabine—POLA1—lymph node—skin cancer	0.00158	0.0242	CbGeAlD
Fludarabine—SLC29A1—head—skin cancer	0.00146	0.0223	CbGeAlD
Fludarabine—DCK—head—skin cancer	0.0014	0.0213	CbGeAlD
Fludarabine—RRM1—lymph node—skin cancer	0.00126	0.0192	CbGeAlD
Fludarabine—SLC29A1—lymph node—skin cancer	0.00102	0.0156	CbGeAlD
Fludarabine—RRM1—E2F transcription factor network—XRCC1—skin cancer	0.000984	0.0603	CbGpPWpGaD
Fludarabine—DCK—lymph node—skin cancer	0.000977	0.0149	CbGeAlD
Fludarabine—RRM1—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000899	0.0551	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000822	0.0504	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00063	0.0386	CbGpPWpGaD
Fludarabine—Anorexia—Imiquimod—skin cancer	0.000593	0.00178	CcSEcCtD
Fludarabine—Hyperglycaemia—Temozolomide—skin cancer	0.000591	0.00177	CcSEcCtD
Fludarabine—Angina pectoris—Fluorouracil—skin cancer	0.000588	0.00176	CcSEcCtD
Fludarabine—Pneumonia—Temozolomide—skin cancer	0.000588	0.00176	CcSEcCtD
Fludarabine—Phlebitis—Docetaxel—skin cancer	0.000585	0.00176	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000579	0.00174	CcSEcCtD
Fludarabine—Body temperature increased—Vemurafenib—skin cancer	0.000576	0.00173	CcSEcCtD
Fludarabine—Pharyngitis—Dactinomycin—skin cancer	0.000576	0.00173	CcSEcCtD
Fludarabine—Pancytopenia—Fluorouracil—skin cancer	0.000573	0.00172	CcSEcCtD
Fludarabine—Neuropathy peripheral—Temozolomide—skin cancer	0.000573	0.00172	CcSEcCtD
Fludarabine—Stomatitis—Temozolomide—skin cancer	0.000569	0.00171	CcSEcCtD
Fludarabine—Urinary tract infection—Temozolomide—skin cancer	0.000568	0.0017	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000567	0.0017	CcSEcCtD
Fludarabine—Deafness—Docetaxel—skin cancer	0.000564	0.00169	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000561	0.00168	CcSEcCtD
Fludarabine—Hepatic failure—Docetaxel—skin cancer	0.000561	0.00168	CcSEcCtD
Fludarabine—Paraesthesia—Imiquimod—skin cancer	0.000558	0.00168	CcSEcCtD
Fludarabine—Chills—Bleomycin—skin cancer	0.000558	0.00167	CcSEcCtD
Fludarabine—Cardiac failure congestive—Docetaxel—skin cancer	0.000556	0.00167	CcSEcCtD
Fludarabine—Dyspnoea—Imiquimod—skin cancer	0.000554	0.00166	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—XRCC1—skin cancer	0.000554	0.034	CbGpPWpGaD
Fludarabine—Alopecia—Bleomycin—skin cancer	0.000549	0.00165	CcSEcCtD
Fludarabine—Erythema multiforme—Dactinomycin—skin cancer	0.000548	0.00165	CcSEcCtD
Fludarabine—Sinusitis—Temozolomide—skin cancer	0.000548	0.00164	CcSEcCtD
Fludarabine—Dyspepsia—Imiquimod—skin cancer	0.000547	0.00164	CcSEcCtD
Fludarabine—Pneumonia—Fluorouracil—skin cancer	0.000541	0.00162	CcSEcCtD
Fludarabine—Decreased appetite—Imiquimod—skin cancer	0.000541	0.00162	CcSEcCtD
Fludarabine—Hypersensitivity—Vemurafenib—skin cancer	0.000537	0.00161	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Imiquimod—skin cancer	0.000537	0.00161	CcSEcCtD
Fludarabine—Fatigue—Imiquimod—skin cancer	0.000536	0.00161	CcSEcCtD
Fludarabine—Visual disturbance—Docetaxel—skin cancer	0.000532	0.0016	CcSEcCtD
Fludarabine—Pain—Imiquimod—skin cancer	0.000532	0.0016	CcSEcCtD
Fludarabine—Acute coronary syndrome—Fluorouracil—skin cancer	0.000531	0.00159	CcSEcCtD
Fludarabine—Myocardial infarction—Fluorouracil—skin cancer	0.000528	0.00158	CcSEcCtD
Fludarabine—Neuropathy peripheral—Fluorouracil—skin cancer	0.000528	0.00158	CcSEcCtD
Fludarabine—Haemoglobin—Temozolomide—skin cancer	0.000527	0.00158	CcSEcCtD
Fludarabine—POLA1—Extension of Telomeres—TERT—skin cancer	0.000526	0.0323	CbGpPWpGaD
Fludarabine—Stomatitis—Fluorouracil—skin cancer	0.000525	0.00157	CcSEcCtD
Fludarabine—Haemorrhage—Temozolomide—skin cancer	0.000524	0.00157	CcSEcCtD
Fludarabine—Urinary tract infection—Fluorouracil—skin cancer	0.000523	0.00157	CcSEcCtD
Fludarabine—Asthenia—Vemurafenib—skin cancer	0.000523	0.00157	CcSEcCtD
Fludarabine—Hypoaesthesia—Temozolomide—skin cancer	0.000522	0.00157	CcSEcCtD
Fludarabine—Pharyngitis—Temozolomide—skin cancer	0.000521	0.00156	CcSEcCtD
Fludarabine—Chills—Dactinomycin—skin cancer	0.00052	0.00156	CcSEcCtD
Fludarabine—Cardiac failure—Docetaxel—skin cancer	0.000517	0.00155	CcSEcCtD
Fludarabine—Pruritus—Vemurafenib—skin cancer	0.000516	0.00155	CcSEcCtD
Fludarabine—Alopecia—Dactinomycin—skin cancer	0.000512	0.00154	CcSEcCtD
Fludarabine—Feeling abnormal—Imiquimod—skin cancer	0.000512	0.00154	CcSEcCtD
Fludarabine—Epistaxis—Fluorouracil—skin cancer	0.000508	0.00152	CcSEcCtD
Fludarabine—Visual impairment—Temozolomide—skin cancer	0.000505	0.00152	CcSEcCtD
Fludarabine—Sinusitis—Fluorouracil—skin cancer	0.000505	0.00152	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000504	0.00151	CcSEcCtD
Fludarabine—Ill-defined disorder—Bleomycin—skin cancer	0.000502	0.00151	CcSEcCtD
Fludarabine—Anaemia—Bleomycin—skin cancer	0.0005	0.0015	CcSEcCtD
Fludarabine—Diarrhoea—Vemurafenib—skin cancer	0.000499	0.0015	CcSEcCtD
Fludarabine—Erythema multiforme—Temozolomide—skin cancer	0.000496	0.00149	CcSEcCtD
Fludarabine—Body temperature increased—Imiquimod—skin cancer	0.000492	0.00148	CcSEcCtD
Fludarabine—Malaise—Bleomycin—skin cancer	0.000488	0.00146	CcSEcCtD
Fludarabine—Haemoglobin—Fluorouracil—skin cancer	0.000486	0.00146	CcSEcCtD
Fludarabine—Leukopenia—Bleomycin—skin cancer	0.000484	0.00145	CcSEcCtD
Fludarabine—Haemorrhage—Fluorouracil—skin cancer	0.000483	0.00145	CcSEcCtD
Fludarabine—Hypoaesthesia—Fluorouracil—skin cancer	0.000481	0.00144	CcSEcCtD
Fludarabine—Pharyngitis—Fluorouracil—skin cancer	0.00048	0.00144	CcSEcCtD
Fludarabine—Cough—Bleomycin—skin cancer	0.000472	0.00142	CcSEcCtD
Fludarabine—Chills—Temozolomide—skin cancer	0.000471	0.00141	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00047	0.0288	CbGpPWpGaD
Fludarabine—Dehydration—Docetaxel—skin cancer	0.000469	0.00141	CcSEcCtD
Fludarabine—Ill-defined disorder—Dactinomycin—skin cancer	0.000468	0.00141	CcSEcCtD
Fludarabine—Anaemia—Dactinomycin—skin cancer	0.000467	0.0014	CcSEcCtD
Fludarabine—Liver function test abnormal—Docetaxel—skin cancer	0.000465	0.0014	CcSEcCtD
Fludarabine—Vomiting—Vemurafenib—skin cancer	0.000464	0.00139	CcSEcCtD
Fludarabine—Alopecia—Temozolomide—skin cancer	0.000463	0.00139	CcSEcCtD
Fludarabine—Myalgia—Bleomycin—skin cancer	0.000461	0.00138	CcSEcCtD
Fludarabine—Rash—Vemurafenib—skin cancer	0.00046	0.00138	CcSEcCtD
Fludarabine—Dermatitis—Vemurafenib—skin cancer	0.000459	0.00138	CcSEcCtD
Fludarabine—Hypersensitivity—Imiquimod—skin cancer	0.000458	0.00137	CcSEcCtD
Fludarabine—Headache—Vemurafenib—skin cancer	0.000457	0.00137	CcSEcCtD
Fludarabine—Malnutrition—Temozolomide—skin cancer	0.000457	0.00137	CcSEcCtD
Fludarabine—Discomfort—Bleomycin—skin cancer	0.000455	0.00137	CcSEcCtD
Fludarabine—Malaise—Dactinomycin—skin cancer	0.000455	0.00137	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000454	0.00136	CcSEcCtD
Fludarabine—Leukopenia—Dactinomycin—skin cancer	0.000452	0.00136	CcSEcCtD
Fludarabine—Asthenia—Imiquimod—skin cancer	0.000446	0.00134	CcSEcCtD
Fludarabine—Confusional state—Bleomycin—skin cancer	0.000445	0.00134	CcSEcCtD
Fludarabine—Anaphylactic shock—Bleomycin—skin cancer	0.000442	0.00133	CcSEcCtD
Fludarabine—Oedema—Bleomycin—skin cancer	0.000442	0.00133	CcSEcCtD
Fludarabine—Pruritus—Imiquimod—skin cancer	0.00044	0.00132	CcSEcCtD
Fludarabine—Infection—Bleomycin—skin cancer	0.000439	0.00132	CcSEcCtD
Fludarabine—Dysphagia—Docetaxel—skin cancer	0.000436	0.00131	CcSEcCtD
Fludarabine—Nausea—Vemurafenib—skin cancer	0.000433	0.0013	CcSEcCtD
Fludarabine—Thrombocytopenia—Bleomycin—skin cancer	0.000433	0.0013	CcSEcCtD
Fludarabine—Arrhythmia—Fluorouracil—skin cancer	0.000432	0.0013	CcSEcCtD
Fludarabine—Myalgia—Dactinomycin—skin cancer	0.00043	0.00129	CcSEcCtD
Fludarabine—Alopecia—Fluorouracil—skin cancer	0.000427	0.00128	CcSEcCtD
Fludarabine—Diarrhoea—Imiquimod—skin cancer	0.000425	0.00128	CcSEcCtD
Fludarabine—Discomfort—Dactinomycin—skin cancer	0.000425	0.00127	CcSEcCtD
Fludarabine—Angina pectoris—Docetaxel—skin cancer	0.000424	0.00127	CcSEcCtD
Fludarabine—Ill-defined disorder—Temozolomide—skin cancer	0.000424	0.00127	CcSEcCtD
Fludarabine—Anaemia—Temozolomide—skin cancer	0.000422	0.00127	CcSEcCtD
Fludarabine—Anorexia—Bleomycin—skin cancer	0.000421	0.00126	CcSEcCtD
Fludarabine—Agitation—Temozolomide—skin cancer	0.00042	0.00126	CcSEcCtD
Fludarabine—Pancytopenia—Docetaxel—skin cancer	0.000414	0.00124	CcSEcCtD
Fludarabine—Oedema—Dactinomycin—skin cancer	0.000412	0.00124	CcSEcCtD
Fludarabine—Malaise—Temozolomide—skin cancer	0.000412	0.00124	CcSEcCtD
Fludarabine—Infection—Dactinomycin—skin cancer	0.000409	0.00123	CcSEcCtD
Fludarabine—Leukopenia—Temozolomide—skin cancer	0.000409	0.00123	CcSEcCtD
Fludarabine—Neutropenia—Docetaxel—skin cancer	0.000407	0.00122	CcSEcCtD
Fludarabine—Thrombocytopenia—Dactinomycin—skin cancer	0.000403	0.00121	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000402	0.00121	CcSEcCtD
Fludarabine—Cough—Temozolomide—skin cancer	0.000398	0.0012	CcSEcCtD
Fludarabine—Paraesthesia—Bleomycin—skin cancer	0.000397	0.00119	CcSEcCtD
Fludarabine—Convulsion—Temozolomide—skin cancer	0.000396	0.00119	CcSEcCtD
Fludarabine—Vomiting—Imiquimod—skin cancer	0.000395	0.00119	CcSEcCtD
Fludarabine—Dyspnoea—Bleomycin—skin cancer	0.000394	0.00118	CcSEcCtD
Fludarabine—Anorexia—Dactinomycin—skin cancer	0.000393	0.00118	CcSEcCtD
Fludarabine—Rash—Imiquimod—skin cancer	0.000392	0.00118	CcSEcCtD
Fludarabine—Dermatitis—Imiquimod—skin cancer	0.000392	0.00118	CcSEcCtD
Fludarabine—Pneumonia—Docetaxel—skin cancer	0.000391	0.00117	CcSEcCtD
Fludarabine—Headache—Imiquimod—skin cancer	0.00039	0.00117	CcSEcCtD
Fludarabine—Anaemia—Fluorouracil—skin cancer	0.000389	0.00117	CcSEcCtD
Fludarabine—Arthralgia—Temozolomide—skin cancer	0.000389	0.00117	CcSEcCtD
Fludarabine—Myalgia—Temozolomide—skin cancer	0.000389	0.00117	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000385	0.00116	CcSEcCtD
Fludarabine—Discomfort—Temozolomide—skin cancer	0.000384	0.00115	CcSEcCtD
Fludarabine—Decreased appetite—Bleomycin—skin cancer	0.000384	0.00115	CcSEcCtD
Fludarabine—Acute coronary syndrome—Docetaxel—skin cancer	0.000383	0.00115	CcSEcCtD
Fludarabine—Renal failure—Docetaxel—skin cancer	0.000382	0.00115	CcSEcCtD
Fludarabine—Neuropathy peripheral—Docetaxel—skin cancer	0.000381	0.00114	CcSEcCtD
Fludarabine—Myocardial infarction—Docetaxel—skin cancer	0.000381	0.00114	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.00038	0.0233	CbGpPWpGaD
Fludarabine—Stomatitis—Docetaxel—skin cancer	0.000379	0.00114	CcSEcCtD
Fludarabine—Pain—Bleomycin—skin cancer	0.000378	0.00113	CcSEcCtD
Fludarabine—Leukopenia—Fluorouracil—skin cancer	0.000377	0.00113	CcSEcCtD
Fludarabine—Confusional state—Temozolomide—skin cancer	0.000376	0.00113	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000375	0.00113	CcSEcCtD
Fludarabine—Anaphylactic shock—Temozolomide—skin cancer	0.000373	0.00112	CcSEcCtD
Fludarabine—Oedema—Temozolomide—skin cancer	0.000373	0.00112	CcSEcCtD
Fludarabine—Infection—Temozolomide—skin cancer	0.00037	0.00111	CcSEcCtD
Fludarabine—Nausea—Imiquimod—skin cancer	0.000369	0.00111	CcSEcCtD
Fludarabine—Epistaxis—Docetaxel—skin cancer	0.000366	0.0011	CcSEcCtD
Fludarabine—Nervous system disorder—Temozolomide—skin cancer	0.000365	0.0011	CcSEcCtD
Fludarabine—Thrombocytopenia—Temozolomide—skin cancer	0.000365	0.00109	CcSEcCtD
Fludarabine—Convulsion—Fluorouracil—skin cancer	0.000364	0.00109	CcSEcCtD
Fludarabine—Feeling abnormal—Bleomycin—skin cancer	0.000364	0.00109	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.00036	0.0221	CbGpPWpGaD
Fludarabine—Hyperhidrosis—Temozolomide—skin cancer	0.00036	0.00108	CcSEcCtD
Fludarabine—Myalgia—Fluorouracil—skin cancer	0.000358	0.00107	CcSEcCtD
Fludarabine—Decreased appetite—Dactinomycin—skin cancer	0.000358	0.00107	CcSEcCtD
Fludarabine—Fatigue—Dactinomycin—skin cancer	0.000355	0.00107	CcSEcCtD
Fludarabine—Anorexia—Temozolomide—skin cancer	0.000355	0.00107	CcSEcCtD
Fludarabine—Discomfort—Fluorouracil—skin cancer	0.000354	0.00106	CcSEcCtD
Fludarabine—Pain—Dactinomycin—skin cancer	0.000352	0.00106	CcSEcCtD
Fludarabine—Haemoglobin—Docetaxel—skin cancer	0.000351	0.00105	CcSEcCtD
Fludarabine—Body temperature increased—Bleomycin—skin cancer	0.000349	0.00105	CcSEcCtD
Fludarabine—Haemorrhage—Docetaxel—skin cancer	0.000349	0.00105	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000347	0.0213	CbGpPWpGaD
Fludarabine—Hypoaesthesia—Docetaxel—skin cancer	0.000347	0.00104	CcSEcCtD
Fludarabine—Confusional state—Fluorouracil—skin cancer	0.000346	0.00104	CcSEcCtD
Fludarabine—Pharyngitis—Docetaxel—skin cancer	0.000346	0.00104	CcSEcCtD
Fludarabine—Anaphylactic shock—Fluorouracil—skin cancer	0.000343	0.00103	CcSEcCtD
Fludarabine—Oedema—Fluorouracil—skin cancer	0.000343	0.00103	CcSEcCtD
Fludarabine—Infection—Fluorouracil—skin cancer	0.000341	0.00102	CcSEcCtD
Fludarabine—Feeling abnormal—Dactinomycin—skin cancer	0.000339	0.00102	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000339	0.00102	CcSEcCtD
Fludarabine—Nervous system disorder—Fluorouracil—skin cancer	0.000337	0.00101	CcSEcCtD
Fludarabine—Thrombocytopenia—Fluorouracil—skin cancer	0.000336	0.00101	CcSEcCtD
Fludarabine—Visual impairment—Docetaxel—skin cancer	0.000336	0.00101	CcSEcCtD
Fludarabine—Paraesthesia—Temozolomide—skin cancer	0.000335	0.001	CcSEcCtD
Fludarabine—Dyspnoea—Temozolomide—skin cancer	0.000332	0.000997	CcSEcCtD
Fludarabine—Erythema multiforme—Docetaxel—skin cancer	0.00033	0.00099	CcSEcCtD
Fludarabine—Dyspepsia—Temozolomide—skin cancer	0.000328	0.000984	CcSEcCtD
Fludarabine—Anorexia—Fluorouracil—skin cancer	0.000327	0.000982	CcSEcCtD
Fludarabine—Body temperature increased—Dactinomycin—skin cancer	0.000326	0.000977	CcSEcCtD
Fludarabine—Hypersensitivity—Bleomycin—skin cancer	0.000325	0.000977	CcSEcCtD
Fludarabine—Decreased appetite—Temozolomide—skin cancer	0.000324	0.000972	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000322	0.000965	CcSEcCtD
Fludarabine—Fatigue—Temozolomide—skin cancer	0.000321	0.000964	CcSEcCtD
Fludarabine—RRM1—Fluoropyrimidine Activity—TP53—skin cancer	0.000321	0.0197	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00032	0.0196	CbGpPWpGaD
Fludarabine—Constipation—Temozolomide—skin cancer	0.000319	0.000956	CcSEcCtD
Fludarabine—Pain—Temozolomide—skin cancer	0.000319	0.000956	CcSEcCtD
Fludarabine—Asthenia—Bleomycin—skin cancer	0.000317	0.000951	CcSEcCtD
Fludarabine—Chills—Docetaxel—skin cancer	0.000313	0.000939	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000313	0.000939	CcSEcCtD
Fludarabine—Pruritus—Bleomycin—skin cancer	0.000313	0.000938	CcSEcCtD
Fludarabine—Arrhythmia—Docetaxel—skin cancer	0.000312	0.000935	CcSEcCtD
Fludarabine—Paraesthesia—Fluorouracil—skin cancer	0.000308	0.000925	CcSEcCtD
Fludarabine—Alopecia—Docetaxel—skin cancer	0.000308	0.000925	CcSEcCtD
Fludarabine—Feeling abnormal—Temozolomide—skin cancer	0.000307	0.000921	CcSEcCtD
Fludarabine—Dyspnoea—Fluorouracil—skin cancer	0.000306	0.000919	CcSEcCtD
Fludarabine—RRM1—E2F transcription factor network—CDKN2A—skin cancer	0.000306	0.0187	CbGpPWpGaD
Fludarabine—Malnutrition—Docetaxel—skin cancer	0.000304	0.000911	CcSEcCtD
Fludarabine—Hypersensitivity—Dactinomycin—skin cancer	0.000304	0.000911	CcSEcCtD
Fludarabine—Dyspepsia—Fluorouracil—skin cancer	0.000302	0.000907	CcSEcCtD
Fludarabine—Decreased appetite—Fluorouracil—skin cancer	0.000298	0.000896	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000296	0.000889	CcSEcCtD
Fludarabine—Asthenia—Dactinomycin—skin cancer	0.000296	0.000887	CcSEcCtD
Fludarabine—Body temperature increased—Temozolomide—skin cancer	0.000295	0.000884	CcSEcCtD
Fludarabine—Pain—Fluorouracil—skin cancer	0.000294	0.000881	CcSEcCtD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TP53—skin cancer	0.000294	0.018	CbGpPWpGaD
Fludarabine—Feeling abnormal—Fluorouracil—skin cancer	0.000283	0.000849	CcSEcCtD
Fludarabine—Diarrhoea—Dactinomycin—skin cancer	0.000282	0.000846	CcSEcCtD
Fludarabine—Vomiting—Bleomycin—skin cancer	0.000281	0.000843	CcSEcCtD
Fludarabine—Anaemia—Docetaxel—skin cancer	0.000281	0.000842	CcSEcCtD
Fludarabine—Rash—Bleomycin—skin cancer	0.000279	0.000836	CcSEcCtD
Fludarabine—Dermatitis—Bleomycin—skin cancer	0.000278	0.000835	CcSEcCtD
Fludarabine—Hypersensitivity—Temozolomide—skin cancer	0.000275	0.000824	CcSEcCtD
Fludarabine—Leukopenia—Docetaxel—skin cancer	0.000272	0.000816	CcSEcCtD
Fludarabine—Body temperature increased—Fluorouracil—skin cancer	0.000271	0.000814	CcSEcCtD
Fludarabine—Asthenia—Temozolomide—skin cancer	0.000267	0.000802	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000267	0.0164	CbGpPWpGaD
Fludarabine—Cough—Docetaxel—skin cancer	0.000265	0.000795	CcSEcCtD
Fludarabine—Pruritus—Temozolomide—skin cancer	0.000264	0.000791	CcSEcCtD
Fludarabine—Convulsion—Docetaxel—skin cancer	0.000263	0.000789	CcSEcCtD
Fludarabine—Nausea—Bleomycin—skin cancer	0.000262	0.000787	CcSEcCtD
Fludarabine—Vomiting—Dactinomycin—skin cancer	0.000262	0.000786	CcSEcCtD
Fludarabine—Rash—Dactinomycin—skin cancer	0.00026	0.00078	CcSEcCtD
Fludarabine—Myalgia—Docetaxel—skin cancer	0.000258	0.000776	CcSEcCtD
Fludarabine—Arthralgia—Docetaxel—skin cancer	0.000258	0.000776	CcSEcCtD
Fludarabine—Diarrhoea—Temozolomide—skin cancer	0.000255	0.000765	CcSEcCtD
Fludarabine—Hypersensitivity—Fluorouracil—skin cancer	0.000253	0.000759	CcSEcCtD
Fludarabine—Confusional state—Docetaxel—skin cancer	0.00025	0.00075	CcSEcCtD
Fludarabine—Anaphylactic shock—Docetaxel—skin cancer	0.000248	0.000744	CcSEcCtD
Fludarabine—Oedema—Docetaxel—skin cancer	0.000248	0.000744	CcSEcCtD
Fludarabine—Infection—Docetaxel—skin cancer	0.000246	0.000739	CcSEcCtD
Fludarabine—Nausea—Dactinomycin—skin cancer	0.000245	0.000734	CcSEcCtD
Fludarabine—Nervous system disorder—Docetaxel—skin cancer	0.000243	0.000729	CcSEcCtD
Fludarabine—Pruritus—Fluorouracil—skin cancer	0.000243	0.000729	CcSEcCtD
Fludarabine—Thrombocytopenia—Docetaxel—skin cancer	0.000243	0.000728	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000239	0.0146	CbGpPWpGaD
Fludarabine—POLA1—Telomere Maintenance—TERT—skin cancer	0.000239	0.0146	CbGpPWpGaD
Fludarabine—Vomiting—Temozolomide—skin cancer	0.000237	0.000711	CcSEcCtD
Fludarabine—Anorexia—Docetaxel—skin cancer	0.000236	0.000709	CcSEcCtD
Fludarabine—Rash—Temozolomide—skin cancer	0.000235	0.000705	CcSEcCtD
Fludarabine—Diarrhoea—Fluorouracil—skin cancer	0.000235	0.000705	CcSEcCtD
Fludarabine—Dermatitis—Temozolomide—skin cancer	0.000235	0.000704	CcSEcCtD
Fludarabine—Headache—Temozolomide—skin cancer	0.000233	0.000701	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000226	0.000677	CcSEcCtD
Fludarabine—Paraesthesia—Docetaxel—skin cancer	0.000223	0.000668	CcSEcCtD
Fludarabine—Nausea—Temozolomide—skin cancer	0.000221	0.000664	CcSEcCtD
Fludarabine—Dyspnoea—Docetaxel—skin cancer	0.000221	0.000663	CcSEcCtD
Fludarabine—Vomiting—Fluorouracil—skin cancer	0.000218	0.000655	CcSEcCtD
Fludarabine—Dyspepsia—Docetaxel—skin cancer	0.000218	0.000655	CcSEcCtD
Fludarabine—Rash—Fluorouracil—skin cancer	0.000216	0.00065	CcSEcCtD
Fludarabine—Dermatitis—Fluorouracil—skin cancer	0.000216	0.000649	CcSEcCtD
Fludarabine—Decreased appetite—Docetaxel—skin cancer	0.000215	0.000646	CcSEcCtD
Fludarabine—Headache—Fluorouracil—skin cancer	0.000215	0.000645	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000214	0.0131	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000214	0.000642	CcSEcCtD
Fludarabine—Fatigue—Docetaxel—skin cancer	0.000214	0.000641	CcSEcCtD
Fludarabine—Pain—Docetaxel—skin cancer	0.000212	0.000636	CcSEcCtD
Fludarabine—Constipation—Docetaxel—skin cancer	0.000212	0.000636	CcSEcCtD
Fludarabine—Feeling abnormal—Docetaxel—skin cancer	0.000204	0.000613	CcSEcCtD
Fludarabine—Nausea—Fluorouracil—skin cancer	0.000204	0.000612	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000203	0.0124	CbGpPWpGaD
Fludarabine—POLA1—Chromosome Maintenance—TERT—skin cancer	0.000199	0.0122	CbGpPWpGaD
Fludarabine—Body temperature increased—Docetaxel—skin cancer	0.000196	0.000588	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000196	0.012	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000185	0.0114	CbGpPWpGaD
Fludarabine—Hypersensitivity—Docetaxel—skin cancer	0.000183	0.000548	CcSEcCtD
Fludarabine—Asthenia—Docetaxel—skin cancer	0.000178	0.000534	CcSEcCtD
Fludarabine—Pruritus—Docetaxel—skin cancer	0.000175	0.000526	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—CDKN2A—skin cancer	0.000172	0.0106	CbGpPWpGaD
Fludarabine—Diarrhoea—Docetaxel—skin cancer	0.00017	0.000509	CcSEcCtD
Fludarabine—Vomiting—Docetaxel—skin cancer	0.000158	0.000473	CcSEcCtD
Fludarabine—Rash—Docetaxel—skin cancer	0.000156	0.000469	CcSEcCtD
Fludarabine—Dermatitis—Docetaxel—skin cancer	0.000156	0.000468	CcSEcCtD
Fludarabine—Headache—Docetaxel—skin cancer	0.000155	0.000466	CcSEcCtD
Fludarabine—POLA1—S Phase—CDK4—skin cancer	0.000148	0.00909	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000148	0.00906	CbGpPWpGaD
Fludarabine—Nausea—Docetaxel—skin cancer	0.000147	0.000442	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDK4—skin cancer	0.000138	0.00844	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000132	0.00811	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PLIN2—skin cancer	0.000129	0.00791	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000114	0.00697	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—skin cancer	0.000105	0.00645	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000104	0.0064	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CSPG4—skin cancer	0.000104	0.00637	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PLIN2—skin cancer	9.93e-05	0.00609	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MLH1—skin cancer	8.88e-05	0.00545	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	8.86e-05	0.00543	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—skin cancer	8.32e-05	0.0051	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CSPG4—skin cancer	8e-05	0.0049	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	7.88e-05	0.00483	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	7.45e-05	0.00457	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ENO2—skin cancer	7.07e-05	0.00433	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ENO2—skin cancer	5.44e-05	0.00333	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDK4—skin cancer	5.05e-05	0.0031	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TERT—skin cancer	5.04e-05	0.00309	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	4.99e-05	0.00306	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDK4—skin cancer	4.51e-05	0.00277	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	4.44e-05	0.00272	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ERCC2—skin cancer	4.1e-05	0.00252	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—skin cancer	3.86e-05	0.00237	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDKN2A—skin cancer	3.45e-05	0.00212	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ERCC2—skin cancer	3.16e-05	0.00194	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTGS2—skin cancer	2.46e-05	0.00151	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TP53—skin cancer	1.92e-05	0.00118	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTGS2—skin cancer	1.89e-05	0.00116	CbGpPWpGaD
